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Abstract 
The optimal chemotherapeutic regimen for cancer of unknown primary (CUP) remains 
uncertain. We encountered 3 cases with CUP who presented with thoracic lymph node 
metastasis. Detailed physical examination and diagnostic tests, including laboratory 
investigations, bronchoscopy, upper and lower gastrointestinal studies, computed 
tomography of the head, neck, abdomen and pelvis and 18F-fluorodeoxyglucose positron 
emission tomography, failed to identify the primary site in these cases. The patients were 
treated with the cisplatin plus docetaxel chemotherapy regimen. Concomitant thoracic 
radiotherapy was conducted in one patient and surgical resection in another. All patients 
showed good response to the chemotherapy and achieved long-term disease-free 
survival. 
 
Introduction 
Despite the development of excellent diagnostic tools, there still remain patients with 
metastatic cancer in whom the site of the primary tumor cannot be determined; these 
patients are defined as having cancer of unknown primary (CUP) [1, 2]. The prevalence  
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of CUP reportedly accounts for approximately 2–5% of all cancer diagnoses [1, 2]. 
Although lymph nodes are the most common metastatic site of CUP [3], involvement of 
thoracic lymph nodes alone in cases of cancer of unknown primary site is quite rare [3–6]. 
We encountered 3 consecutive patients with CUP with metastases primarily involving the 
mediastinal lymph nodes during a 5-year period at our institute. All 3 patients were 
treated by combined cisplatin (CDDP) plus docetaxel (DOC) chemotherapy. All showed 
good responses to this chemotherapy, with prolonged disease-free survival. We describe 
our experience with these 3 cases along with a review of the relevant literature. 
Case Presentation 
Case 1 
A 55-year-old man was referred to our hospital because of abnormal findings on chest computed 
tomography (CT) in October 2002. The patient had no history of smoking or any significant medical 
history. Physical examination revealed no abnormal findings except left supraclavicular lymph node 
swelling. Serum carcinoembryonic antigen (CEA) was elevated (11.6 ng/ml, normal <2.5 ng/ml). 
Although chest radiography was normal, chest CT showed enlarged nodes (para-aortic, aortopulmonary 
window area, fig. 1). Supraclavicular lymph node biopsy was performed and the histopathological 
examination revealed undifferentiated carcinoma. 
18F-fluorodeoxyglucose positron emission 
tomography (FDG-PET) conducted after supraclavicular lymph node resection revealed positive 
accumulation in the mediastinal lymph nodes, but no other abnormalities (fig. 1). The patient was 
treated with 4 courses of CDDP/DOC chemotherapy. Shrinkage of the mediastinal and supraclavicular 
lymph nodes was noted on chest CT (fig. 1) and the serum CEA level also decreased from 11.6 to 2.1 
ng/ml. The patient is still alive, 68 months to date, after the chemotherapy. 
Case 2 
A 55-year-old man was hospitalized because of precordial pain and fever in January 2006. He was 
diagnosed as having pericarditis based on the presence of pericardial effusion, elevated T waves in leads 
V1–V6 on the electrocardiogram and the presence of serum markers of inflammation (C-reactive 
protein, CRP). However, subcarinal lymph node enlargement was observed on chest CT and he was 
referred to our hospital. The patient had a history of smoking (70 pack-years). Physical examination 
revealed no abnormal findings, except the high fever. Enlargement of the subcarinal lymph node was 
observed on chest CT and the node was found to be positive on FDP-PET (fig. 2). Marked elevation of 
the serum level of soluble interleukin (sIL)-2 was noted (2,070 U/ml); however, other tumor marker 
levels were within normal ranges. Since transbronchial aspiration cytology failed to yield an exact 
histological diagnosis, lymph node resection was performed via video-associated thoracoscopic surgery 
(VATS). The histological findings revealed that large atypical cells with clear nucleolus proliferated 
solidly with neutrophil infiltration and lymphoid follicle formation. The immunological staining 
showed that cytokeratin (CK) markers (CK7, CK22, CK5/6 and CAM5.2) were positive, whereas CD3, 
CD5, CD20 and CD30 were negative, which confirmed the presence of an undifferentiated carcinoma. 
Based on results of the general physical and other examinations, the patient was diagnosed as having 
CUP. However, the serum markers of inflammation and elevated soluble IL-2 levels were persistent and 
the fever also persisted postoperatively. The patient was then treated with 2 courses of CDDP/DOC 
chemotherapy. The fever resolved after the chemotherapy, along with decrease of the serum CRP and 
sIL-2 (0.02 and 439 U/ml, respectively). Since the chemotherapy, the patient has remained disease-free 
and asymptomatic for 31 months to date. 
Case 3 
A 66-year-old man was followed at our hospital after left lower lobectomy for lung cancer 
(squamous cell carcinoma, SCC) in September 2001. He gave a history of smoking (40 pack-years) prior 
to the operation. The serum CEA rose to 4.4 ng/ml in June 2006. Chest radiography and CT revealed 
upper mediastinal lymph node enlargement, and FDG-PET showed positive accumulation in the node; 
however, no other abnormalities were detected (fig. 3a). There were no abnormalities on physical  
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examination either. A needle biopsy of the node was performed and the findings were consistent with 
undifferentiated carcinoma, which was apparently different in histology from that of the previously 
diagnosed pulmonary SCC. He was diagnosed as having CUP and was treated with 2 courses of 
CDDP/DOC chemotherapy plus concurrent thoracic radiotherapy (60 Gy/2 Gy × 30 fractions). The 
node was found to have reduced in size on chest radiography and CT (fig. 3b), and the elevated serum 
CEA level also decreased from 11.5 to 1.7 ng/dl. 
In all 3 patients, detailed medical histories, thorough physical assessments, including laboratory 
investigations (blood analysis, urinalysis, stool occult blood test), bronchoscopy, upper and lower 
gastrointestinal studies, and CT of the brain, neck, abdomen and pelvis failed to identify the primary site 
of the cancer. The chemotherapy cycles were repeated every 3–4 weeks. All 3 patients are still alive 
without any sign of disease relapse on serial tests, including tests for tumor markers and radiographic 
examinations. The disease-free survivals were 68 months in Case 1, 31 months in Case 2 and 29 months 
in Case 3. 
Discussion 
Neither standard nor optimal chemotherapeutic regimens have yet been determined 
because of the complex and heterogeneous presentations of patients with CUP. 
Historically, the empiric approach, including platinum-containing regimens, has yielded 
response rates of between 30 and 40% and the median survival time has been reported to 
be approximately 8 months [1, 2]. Among the new agents which became available in the 
1990s, the taxanes were reported to show significant activity against CUP. Based on the 
results of several studies [7–9] and 2 reviews [10, 11], it appears that platinum compounds 
plus taxanes may prove to be as effective or more effective than previous regimens. Our 
present cases treated with CDDP/DOC lend support to the notion that this regimen is 
active as empiric chemotherapy in patients with CUP, especially in cases with thoracic 
lesions. 
In addition, all 3 cases exhibited prolonged disease-free survival after the 
chemotherapy. Follow-up of more than 1 year is not usually reported in prospective 
studies of CUP, but several studies conducted on small numbers of patients have 
demonstrated the patients to be alive and free of disease progression for several years. 
Hess et al. [3] summarized 1,000 consecutive cases of CUP and analyzed the relationship 
between the clinical features and survival. They demonstrated that CUP patients with 1 or 
2 metastatic sites, but non-adenocarcinoma histology, and no liver, bone, adrenal or 
pleural metastasis, had the longest median survival time of 40 months. Greco et al. [8] also 
showed that although the median survival time was only 9.2 months, the 5-year survival 
rate was 10%. Thus, there have been long-term survivors among patients with CUP [12]. 
In addition, the predominant site of tumor metastasis was mediastinal lymph nodes in 
our cases. It was reported by Greco et al. [10] that responses to chemotherapy varied 
depending on the organs/sites of CUP and that the response rates were higher in patients 
with lymph node metastases than those with involvement of other organs (liver, bone, 
lungs). Although the differences in response rates among patients with different locations 
of the metastatic lymph nodes remain to be clarified, our experience suggests that 
CDDP/DOC is a useful chemotherapeutic regimen for CUP patients with thoracic lymph 
node involvement. 
Riquet et al. [6] reported several CUP cases with metastatic thoracic lymph node 
involvement and suggested that long-term survival could be obtained by resection of the 
nodes in certain cases. In the present series, Case 2 underwent thoracic lymph node 
resection, but this did not result in normalization of the serum markers of inflammation. 
The subsequently administered CDDP/DOC chemotherapy, however, effectively reduced  
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the levels of these markers. Thus, we consider that the adjuvant chemotherapy with 
CDDP/DOC to have been useful for controlling the disease in Case 2. 
In addition to CDDP/DOC chemotherapy, concurrent thoracic radiotherapy was 
performed in Case 3. Both CDDP and DOC may be expected to exert considerable 
synergistic interactions with concurrent radiotherapy [13, 14]. Thus, concurrent 
radiotherapy could be undertaken with the administration of chemotherapeutic agents as 
radiosensitizers. Furthermore, the radiosensitizing effect of DOC is 10 times higher than 
that of paclitaxel at equimolar concentrations [15]. Thus, we believe that combined 
chemoradiotherapy can contribute to a better outcome and that radiotherapy may be a 
valuable therapeutic tool for locally advanced disease in patients with CUP, especially in 
those with thoracic metastases. In regard to the risk of the combined modality therapy 
contributing to the development of radiation pneumonitis, it has been shown that CDDP 
and DOC administration is feasible [14] and well-tolerated in lung cancer patients. Thus, 
this regimen may also be useful with concurrent radiotherapy for treating thoracic 
involvement in patients with CUP. 
It has been demonstrated that FDP-PET scanning is useful for detecting unknown 
primary sites in patients with CUP and/or can serve as an additional diagnostic tool in 
CUP patients [16, 17]. Although FDG-PET failed to locate the primary sites in our cases, 
this examination should be carried out to diagnose patients with CUP. In addition, the 
information from FDG-PET scanning in our cases was valuable for selecting the 
appropriate therapeutic strategies in Cases 2 and 3. Surgical resection and radiotherapy 
were performed based on the disease locations revealed by FDG-PET in these cases. Thus, 
FDG-PET has a beneficial impact on therapeutic management [18] and may even allow a 
specific chemotherapeutic regimen to be selected for the target organ in patients with 
CUP. Further evaluation of this new diagnostic tool in this context is, therefore, 
warranted. 
In summary, we have described herein 3 cases of CUP who responded well to 
combined modality therapy, including CDDP/DOC chemotherapy, and have shown 
prolonged disease-free survival. 
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Fig. 1. Chest CT before chemotherapy showing enlarged mediastinal lymph nodes, and FDG-PET 
revealing positive accumulation in the mediastinal lymph nodes (Before). After four cycles of 
CDDP/DOC chemotherapy, shrinkage of the nodes was seen (After) in Case 1. 
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Fig. 2. Chest CT showing enlargement of a subcarinal lymph node, and FDG-PET showing strong 
accumulation in the subcarinal lymph node (Before). After the lymph node resection and two cycles of 
CDDP/DOC chemotherapy, no accumulation of FDG-PET was observed (After) in Case 2. 
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Fig. 3. a Chest radiograph, CT and FDG-PET before chemotherapy showing upper mediastinal lymph 
node enlargement in Case 3. b Chest radiograph and CT showing shrinkage of the lymph node after 2 
cycles of CDDP/DOC chemotherapy with concurrent thoracic radiotherapy in Case 3. 
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